CN1732938A - Orally integrating tablet of compound paracetamol - Google Patents
Orally integrating tablet of compound paracetamol Download PDFInfo
- Publication number
- CN1732938A CN1732938A CN 200510029230 CN200510029230A CN1732938A CN 1732938 A CN1732938 A CN 1732938A CN 200510029230 CN200510029230 CN 200510029230 CN 200510029230 A CN200510029230 A CN 200510029230A CN 1732938 A CN1732938 A CN 1732938A
- Authority
- CN
- China
- Prior art keywords
- weight
- oral cavity
- cavity disintegration
- disintegration tablet
- filler
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Abstract
Disclosed is an orally integrating tablet of compound paracetamol, which comprises 10-40 wt% of paracetamol, 0.5-5 wt% of d-pesudoephedrine hydrochloride, 0.25-2 wt% of dextromethorphan hydrobromide, 0.1-1 wt% of chlorpheniramine maleate, 5-65 wt% of bulking agent, 10-30 wt% of disintegrating agent, 1-20 wt% of flavorings, 5-20 wt% of sweetener, 0.5-3 wt% of flavouring essence, and 0.5-5 wt% of lubricating agent.
Description
Technical field
The present invention relates to a kind of compound medicine tablet for the treatment of flu, relate in particular to a kind of Aminodyne Compound oral cavity disintegration tablet.
Background technology
Flu is commonly called as " cold ", is a kind of respiratory tract commonly encountered diseases that is caused by multiple virus.Because the multiformity and the rapidity of cold virus variation make people hard to guard against to catching a cold.Common cold treatment should etiological treatment, and simultaneously, relief of symptoms also is one of key of common cold treatment comprehensively.Therefore, the compound medicine for the treatment of cold symptoms such as fever, cough, nasal obstruction, watery nasal discharge simultaneously is the main product in present coldrex market.In compound recipe cold medicine prescription commonly used, acetaminophen belongs to the phenyl amines antipyretic analgesic, is the maincenter PGSI, the similar aspirin of its refrigeration function, and side effect is little; Pseudoephedrine hydrochloride is an adrenoceptor agonists, can make the bronchial mucosa vasoconstriction, alleviates edema, and action temperature and lasting, but relieving asthma and nasal obstruction; Dextromethorphan hydrobromide is a central antitussive, and intensity and codeine are suitable, and do not have addiction; Chlorphenamine maleate is a histamine H
1Receptor antagonist has resisting allergic rhinitis and sedation.The appropriate proportioning of said medicine is formed compound recipe, can effectively alleviate various cold symptoms.
At present, commercially available coldrex mostly is tablet, capsule, granule etc., needs water just can take, especially concerning the flu patient of infant, old people and dysphagia, very inconvenience, and the disintegration rate of these medicines is relatively slow, so its dissolution rate and onset are also very slow.Though the oral cavity disintegration tablet of research bibliographical information flu class medicine is arranged, as application number is that 200410007552.1 patent application discloses a kind of acetaminophen oral cavity disintegration tablet, it is rapid, rapid-action that this oral cavity disintegration tablet has a disintegrate, advantage such as taking convenience, mouthfeel are good.But this oral cavity disintegration tablet is single pharmaceutical compositions preparation, can not effectively alleviate various cold symptoms comprehensively.Application number is that 200310121987.4 patent application discloses a kind of Paracetamol Pseudoephedrine desintegration piece and preparation method thereof, is the oral cavity disintegration tablet of compound recipe cold medicine.But its principal agent is made up of acetaminophen, pseudoephedrine hydrochloride, chlorphenamine maleate, and obviously, this drug prescription does not have mitigation to the cold cough symptom, has very big defective aspect comprehensive alleviation cold symptoms.
Yet, prepare the compound recipe flu oral cavity disintegration tablet of alleviating cold symptoms more comprehensively, especially when containing the pharmaceutical compositions of this serious bitter taste of dextromethorphan hydrobromide in the prescription, this will make the taste masking difficulty in the medication preparation seriously strengthen.Because this is to requiring the directly disintegrating tablet of disintegrate in the oral cavity, bitterness is difficult to allow the patient accept, thereby makes the taste masking difficulty in the medication preparation process strengthen.Can better cover bitterness though adopt the powder coating technology that various pharmaceutical compositions are handled, this complex process, thus increasing manufacturing cost, this can make the cost performance of oral cavity disintegration tablet of compound recipe cold medicine be difficult to allow the patient accept again.
Therefore, when comprehensively alleviating cold symptoms, onset is more rapid, take the compound recipe cold medicine more convenient, that mouthfeel is more good is that the scientific research personnel makes great efforts to wish the technical barrier that solves always.
Summary of the invention
The objective of the invention is provides a kind of Aminodyne Compound oral cavity disintegration tablet in order to solve above-mentioned defective of the prior art.Aminodyne Compound oral cavity disintegration tablet of the present invention not only can be alleviated various cold symptoms comprehensively; And oral cavity disintegration tablet of the present invention is in the oral cavity during disintegrate, and bitterness is light or do not feel bitterness, thereby the patient also easily accepts.
Aminodyne Compound oral cavity disintegration tablet of the present invention contains the principal agent and the accessory drugs of recipe quantity.Wherein, acetaminophen, pseudoephedrine hydrochloride, dextromethorphan hydrobromide, chlorphenamine maleate, filler, disintegrating agent and lubricant in the Aminodyne Compound oral cavity disintegration tablet of the present invention all can be with reference to prior art, and it also contains the odor mask of 1～20 weight %, the sweeting agent of 5～20 weight %, the edible essence of 0.5～3 weight %.They can be covered the bitterness of the acetaminophen in the medicine, pseudoephedrine hydrochloride, dextromethorphan hydrobromide and chlorphenamine maleate, do not make this oral cavity disintegration tablet bitter or bitterness is lighter.
In Aminodyne Compound oral cavity disintegration tablet of the present invention, preferred 10～40 weight % of acetaminophen, more preferably 10～30 weight %, most preferably 19.8 weight %; Preferred 0.5～5 weight % of pseudoephedrine hydrochloride, more preferably 1.9 weight %; Preferred 0.25～2 weight % of dextromethorphan hydrobromide, more preferably 0.25～1 weight %, most preferably 0.6 weight %; Preferred 0.1～1 weight % of chlorphenamine maleate, more preferably 0.2 weight %; Preferred 5～65 weight % of filler, more preferably 10～60 weight %, most preferably 39.6 weight %; Preferred 10～30 weight % of disintegrating agent, more preferably 10～20 weight %, most preferably 12.5 weight %; The preferred 14.8 weight % of odor mask; The preferred 7.4 weight % of sweeting agent; The preferred 2 weight % of edible essence; Preferred 0.5～5 weight % of lubricant, more preferably 1.2 weight %, more than all refer to account for the percentage ratio of Aminodyne Compound oral cavity disintegration tablet gross weight.
In the present invention, preferred water-soluble filler of described filler and/or water-insoluble filler, this water-soluble filler are mannitol, sorbitol and/or xylitol, and this water-insoluble filler is microcrystalline Cellulose, lactose, starch and/or pregelatinized Starch.
This disintegrating agent can make tablet disintegrate rapidly in the oral cavity, preferred cross-linking sodium carboxymethyl cellulose (CMCNa), crospolyvinylpyrrolidone (PVP), low-substituted hydroxypropyl cellulose (L-HPC) and/or crosslinked carboxymethyl fecula sodium (CMSNa).
This odor mask can be trisodium citrate and/or fruity odor mask, and this fruity odor mask should can be selected various fruity odor masks according to patient's taste difference, as orange flavor, hami melon flavor, Fructus Fragariae Ananssae flavor, Fructus Musae flavor or Fructus Ananadis comosi flavor odor mask.It can cover the effect that bitter taste of drug is improved taste and mouthfeel.
This sweeting agent can be a various sweeting agent of the prior art, is preferably cyclamate, aspartame and/or stevioside, considers the potential toxicity of synthetic sweetener, if can reach the sweet taste requirement during use, reduces its consumption as far as possible.
This edible essence can be Herba Menthae essence and/or fruit essence, fruit essence should be selected according to corresponding fruity odor mask, be that fruit essence is consistent with fruity odor mask taste, correspondingly be orange flavor, hami melon flavor, Fructus Fragariae Ananssae flavor, Fructus Musae flavor or Fructus Ananadis comosi flavor essence, purpose is to make tablet to have pleasant fruit abnormal smells from the patient, preferably adds Herba Menthae essence simultaneously, makes the tablet inlet produce the algefacient sensation, improve mouthfeel, help taste masking.
This lubricant can be magnesium stearate and/or Pulvis Talci.
If when Aminodyne Compound oral cavity disintegration tablet of the present invention adopts wet granulation technology, also contain binding agent, this binding agent is the polyvinylpyrrolidone of 2～5 weight % of recipe quantity preferably.
Positive progressive effect of the present invention is: Aminodyne Compound oral cavity disintegration tablet of the present invention is compared with the Aminodyne Compound ordinary tablet possesses following advantage:
1, disintegrate is rapid, and the medicine stripping is accelerated, thereby quickens drug effect;
2, taking convenience need not water, relies on saliva can make the medicine disintegrate in the oral cavity, and the flu patient who therefore is particularly suitable for infant, old people and dysphagia takes;
3, owing to medicine i.e. disintegrate before entering gastrointestinal tract, thereby enlarge the distribution area of medicine in gastrointestinal tract, so both helped medicine and fully absorbed, improve bioavailability, avoided of the stimulation of the local accumulation of drug dose again mucosa;
4, medicine of the present invention has been covered the bitterness of several drugs preferably, and cool taste is beneficial to the compliance that improves treatment.
Based on above-mentioned advantage, the invention solves the technical barrier on Aminodyne Compound Orally disintegrating tablet recipe and the preparation technology, reach the purpose that the medicine disintegrate is rapid, stripping is fast, thereby can improve drug effect speed, quickening alleviation cold symptoms; By adopting the present invention's prescription to make medicine possess good mouthfeel, avoid the use of powder coating technology simultaneously in addition, reduced manufacturing cost, improved the cost performance of medicine of the present invention.
The specific embodiment
Embodiment 1
Table 1
1000 consumptions of sequence number component (g) proportions (%)
Acetaminophen 80 19.8
Pseudoephedrine hydrochloride 7.5 1.9
1. dextromethorphan hydrobromide 2.5 0.6
Chlorphenamine maleate 1.0 0.2
Microcrystalline Cellulose 80 19.8
Mannitol 80 19.8
Aspartame 30 7.4
Trisodium citrate 30 7.4
2. crospolyvinylpyrrolidone 50 12.4
Orange bitter in the mouth flavor odor mask 30 7.4
Orange flavor powdered flavor 4.0 1.0
Herba Menthae essence 4.0 1.0
Magnesium stearate 5.0 1.2
Technology: method will 1. the class mixing of materials be even to adopt equivalent to progressively increase, again with direct compression behind the 2. class material mixing.The gained tablet hardness is 2.2 ± 0.1kg (the YD-20 type intelligence tablet hardness instrument that adopts Radio Factory of Tianjin Univ. to produce is measured).
Embodiment 2
Table 2
1000 consumptions of sequence number component (g) proportions (%)
Acetaminophen 100 10.0
Pseudoephedrine hydrochloride 5.0 0.5
1. dextromethorphan hydrobromide 2.5 0.25
Chlorphenamine maleate 1.0 0.1
Starch 350 35.0
Mannitol 300 30.0
2. crospolyvinylpyrrolidone (interior 50
Add) 5.0
Aspartame 50 5.0
Trisodium citrate 5.0 0.5
3. polyvinylpyrrolidone 21.5 2.15
Crospolyvinylpyrrolidone (outer 50
Add) 5.0
4. orange bitter in the mouth flavor odor mask 5.0 0.5
Orange flavor powdered flavor 15 1.5
Herba Menthae essence 15 1.5
Magnesium stearate 30 3.0
Technology:
Method will 1. the class mixing of materials be even to adopt equivalent to progressively increase, again with 2. class material mixing, add 10% polyvinylpyrrolidone aqueous solution 215mL then and prepare soft material, cross 40 mesh sieves and prepare wet granular, 45 ℃ of oven dry down, dried granule and 4. class add evenly back tabletting of mixing of materials, the gained tablet hardness is 2.5 ± 0.1kg (the YD-20 type intelligence tablet hardness instrument that adopts Radio Factory of Tianjin Univ. to produce is measured).
Embodiment 3
Table 3
1000 consumptions of sequence number component (g) proportions (%)
Acetaminophen 400 40.0
Pseudoephedrine hydrochloride 50 5.0
1. dextromethorphan hydrobromide 20 2.0
Chlorphenamine maleate 10 1.0
Lactose 20 2.0
Sorbitol 30 3.0
Crospolyvinylpyrrolidone 80 8.0
2. crosslinked carboxymethyl fecula sodium 20 2.0
Cyclamate 150 15.0
Trisodium citrate 100 10.0
Fructus Musae bitter in the mouth flavor odor mask 100 10.0
Fructus Musae flavor powdered flavor 5.0 0.5
Magnesium stearate 15 1.5
Technology:
Method will 1. the class mixing of materials be even to adopt equivalent to progressively increase, again with direct compression behind the 2. class material mixing.The gained tablet hardness is 2.3 ± 0.1kg (the YD-20 type intelligence tablet hardness instrument that adopts Radio Factory of Tianjin Univ. to produce is measured).
Embodiment 4
Table 4
1000 consumptions of sequence number component (g) proportions (%)
Acetaminophen 223 22.3
Pseudoephedrine hydrochloride 24 2.4
1. dextromethorphan hydrobromide 10 1.0
Chlorphenamine maleate 5 0.5
Microcrystalline Cellulose 96 9.6
Xylitol 111 11.1
2. cross-linking sodium carboxymethyl cellulose (interior 160
Add) 16.0
Stevioside 88 8.8
Trisodium citrate 48 4.8
3. polyvinylpyrrolidone 20 2.0
Cross-linking sodium carboxymethyl cellulose (outer 80
Add) 8.0
Low-substituted hydroxypropyl cellulose 60 6.0
4. Fructus Mali pumilae bitter in the mouth flavor odor mask 48 4.8
Fructus Mali pumilae flavor powdered flavor 16 1.6
Herba Menthae essence 6 0.6
Pulvis Talci 3 0.3
Magnesium stearate 2 0.2
Technology:
Method will 1. the class mixing of materials be even to adopt equivalent to progressively increase, again with 2. class material mixing, add 20% polyvinylpyrrolidone aqueous solution 100mL then and prepare soft material, cross 40 mesh sieves and prepare wet granular, 45 ℃ of oven dry down, dried granule and 4. class add evenly back tabletting of mixing of materials, the gained tablet hardness is 2.2 ± 0.1kg (the YD-20 type intelligence tablet hardness instrument that adopts Radio Factory of Tianjin Univ. to produce is measured).
Embodiment 5
Table 5
1000 consumptions of sequence number component (g) proportions (%)
Acetaminophen 187 18.7
Pseudoephedrine hydrochloride 19 1.9
1. dextromethorphan hydrobromide 6.0 0.6
Chlorphenamine maleate 2.0 0.2
Pregelatinized Starch 187 18.7
Mannitol 110 11.0
Crospolyvinylpyrrolidone 117 11.7
Aspartame 200 20.0
2. trisodium citrate 70 7.0
Fructus Fragariae Ananssae bitter in the mouth flavor odor mask 70 7.0
Fructus Fragariae Ananssae flavor powdered flavor 20 2.0
Herba Menthae essence 5.0 0.5
Magnesium stearate 7.0 0.7
Technology:
Method will 1. the class mixing of materials be even to adopt equivalent to progressively increase, again with direct compression behind the 2. class material mixing.The gained tablet hardness is 2.5 ± 0.1kg (the YD-20 type intelligence tablet hardness instrument that adopts Radio Factory of Tianjin Univ. to produce is measured).
Embodiment 6
Table 6
1000 consumptions of sequence number component (g) proportions (%)
Acetaminophen 200 20.0
Pseudoephedrine hydrochloride 27 2.7
1. dextromethorphan hydrobromide 8.0 0.8
Chlorphenamine maleate 3.0 0.3
Microcrystalline Cellulose 115 11.5
Sorbitol 67 6.7
Crospolyvinylpyrrolidone 166 16.6
Aspartame 20 20.0
2. trisodium citrate 67 6.7
Hami melon bitterness odor mask 67 6.7
Hami melon powdered flavor 18 1.8
Herba Menthae essence 12 1.2
Pulvis Talci 17 1.7
Magnesium stearate 33 3.3
Technology:
Method will 1. the class mixing of materials be even to adopt equivalent to progressively increase, again with direct compression behind the 2. class material mixing.The gained tablet hardness is 2.3 ± 0.1kg (the YD-20 type intelligence tablet hardness instrument that adopts Radio Factory of Tianjin Univ. to produce is measured).
Embodiment 7
Table 7
1000 consumptions of sequence number component (g) proportions (%)
Acetaminophen 259 25.9
Pseudoephedrine hydrochloride 21 2.1
1. dextromethorphan hydrobromide 6.0 0.6
Chlorphenamine maleate 3.0 0.3
Microcrystalline Cellulose 156 15.6
Mannitol 156 15.6
Crospolyvinylpyrrolidone 130 13.0
Aspartame 104 10.4
2. trisodium citrate 61 6.1
Fructus Ananadis comosi bitterness odor mask 52 5.2
Fructus Ananadis comosi powdered flavor 16 1.6
Herba Menthae essence 10 1.0
Magnesium stearate 26 2.6
Technology:
Method will 1. the class mixing of materials be even to adopt equivalent to progressively increase, again with direct compression behind the 2. class material mixing.The gained tablet hardness is 2.2 ± 0.1kg (the YD-20 type intelligence tablet hardness instrument that adopts Radio Factory of Tianjin Univ. to produce is measured).
Effect embodiment 1 external disintegrate
The Aminodyne Compound oral cavity disintegration tablet of getting a slice embodiment 1～7 preparation places culture dish, slowly drips 37 ℃ of water 2mL, timing 1 minute.Observe whether disintegrate fully of this product, whether have hard core, the results are shown in Table 8.
Table 8
| Oral cavity disintegration tablet of the present invention | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Whether disintegrate is complete | Fully | Fully | Fully | Fully | Fully | Fully | Fully |
| Have or not hard core | Do not have | Do not have | Do not have | Do not have | Do not have | Do not have | Do not have |
Conclusion: there is not hard core in the disintegrate fully in external 1 minute of the Aminodyne Compound oral cavity disintegration tablet of the embodiment of the invention 1～7.
Disintegrate in effect embodiment 2 bodies
Attempted voluntarily by the volunteer, the Aminodyne Compound oral cavity disintegration tablet of getting a slice embodiment 1～7 preparation is contained in the oral cavity, does not chew, and observes the time of complete disintegrate, the results are shown in Table 9.
Table 9
| Oral cavity disintegration tablet of the present invention | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Complete disintegration time (second) | 40 | 55 | 45 | 55 | 45 | 40 | 45 |
Conclusion: the Aminodyne Compound oral cavity disintegration tablet of the embodiment of the invention 1～7 disintegrate fully within 55 seconds in vivo.
Effect embodiment 3 dissolutions
Dissolution method second method that the oral cavity disintegration tablet of preparation among the embodiment 1～7 is recorded according to " Pharmacopoeia of People's Republic of China 2005 editions " is measured the dissolution of acetaminophen, minute is 30 minutes, and be contrast with commercially available homemade acetaminophen compound ordinary tablet (Shanghai nine good fortune pharmaceutical factories produce " Xin Paerke "), the results are shown in Table 10.
Table 10
| The sample title | Average stripping quantity (%) | The P value |
| Embodiment 1 | 99.4 | ＜0.05 |
| Embodiment 2 | 97.8 | ＜0.05 |
| Embodiment 3 | 98.9 | ＜0.05 |
| Embodiment 4 | 98.5 | ＜0.05 |
| Embodiment 5 | 99.0 | ＜0.05 |
| Embodiment 6 | 98.2 | ＜0.05 |
| Embodiment 7 | 99.0 | ＜0.05 |
| The acetaminophen compound ordinary tablet | 82.3 |
Effect embodiment 4 Aminodyne Compound oral cavity disintegration tablets and " Paracetamol Pseudoephedrine desintegration piece " comparison aspect mouthfeel
Adopt the double blinding volunteer to taste method, 56 volunteers are divided into A, B, C, D, E, F, G group, every group 8 people at random.At first, each organizes the oral cavity disintegration tablet that the volunteer takes embodiment 1～7 respectively; Afterwards, allow A, B, C, D, E, F, G group volunteer all take the described disintegrating tablet of " Paracetamol Pseudoephedrine desintegration piece " (number of patent application 200310121987.4) again, with bitterness more between the two.With " good (5 minutes), better (4 minutes), general (3 minutes), relatively poor (2 minutes), poor (1 minute) " five grades the taste of individual sample is made an appraisal respectively.The volunteer gargles 3 times with clear water at the tempus intercalare of tasting different samples, the results are shown in Table 11 after the trial test.
Table 11
| Volunteer's marking (X ± SD) | The P value | ||
| The A group | Embodiment 1 oral cavity disintegration tablet Paracetamol Pseudoephedrine desintegration piece | 4.2±0.8 1.8±0.6 | P＜0.05 |
| The B group | Embodiment 2 oral cavity disintegration tablet Paracetamol Pseudoephedrine desintegration pieces | 4.0±0.7 1.7±0.6 | P＜0.05 |
| The C group | Embodiment 3 oral cavity disintegration tablet Paracetamol Pseudoephedrine desintegration pieces | 4.1±0.9 1.8±0.7 | P＜0.05 |
| The D group | Embodiment 4 oral cavity disintegration tablet Paracetamol Pseudoephedrine desintegration pieces | 4.2±0.7 1.7±0.5 | P＜0.05 |
| The E group | Embodiment 5 oral cavity disintegration tablet Paracetamol Pseudoephedrine desintegration pieces | 4.2±0.8 1.5±0.3 | P＜0.05 |
| The F group | Embodiment 6 oral cavity disintegration tablet Paracetamol Pseudoephedrine desintegration pieces | 4.1±0.5 1.6±0.3 | P＜0.05 |
| The G group | Embodiment 7 oral cavity disintegration tablet Paracetamol Pseudoephedrine desintegration pieces | 4.2±0.5 1.5±0.5 | P＜0.05 |
The result shows: the volunteer accepts the taste of " Paracetamol And Chlorphenamine And Pseudoephedrine oral cavity disintegration tablet " is difficult, and satisfied to Aminodyne Compound oral cavity disintegration tablet taste of the present invention.
The refrigeration function test of effect embodiment 5 Aminodyne Compound oral cavity disintegration tablets
Get 16 of the healthy rabbits of 39.0 ± 0.2 ℃ of body temperature, be divided into 2 groups at random, 8 every group.Every rabbit is injected typhoid fever, paratyphoid fever, second triple vaccine 0.5ml/kg by auricular vein, treats that rabbit body temperature surpasses normal body temperature and begins administration after more than 1.0 ℃.The test group feed is pressed the oral cavity disintegration tablet of embodiment 1 preparation, the dosage of acetaminophen is 20mg/kg, the commercially available homemade acetaminophen compound ordinary tablet of matched group feed (" Xin Paerke " that Shanghai nine good fortune pharmaceutical factories produce), acetaminophen dosage is identical with test group.Measure rabbit body temperature in per 15 minutes after the administration, the results are shown in Table 12.
Table 12
| Group | Drop-out value after the administration during the relative administration of different time body temperature (℃, X ± SD) | ||||
| 15min | 30min | 45min | 60min | 75min | |
| Matched group | 0 | 0 | 0.4±0.2 | 0.6±0.3 | 0.8±0.4 |
| Test group | 0 | 0.5±0.2 | 0.8±0.3 | 0.9±0.3 | 0.9±0.3 |
Conclusion: compound recipe acetyl aminophenol oral cavity disintegration tablet of the present invention to the rabbit cool effect obviously faster than commercially available homemade acetaminophen compound ordinary tablet.
All raw materials are commercially available in the foregoing description.
Claims (9)
1, a kind of Aminodyne Compound oral cavity disintegration tablet is characterized in that the pseudoephedrine hydrochloride of it acetaminophen that comprises 10～40 weight %, 0.5～5 weight %, the dextromethorphan hydrobromide of 0.25～2 weight %, the chlorphenamine maleate of 0.1～1 weight %, the filler of 5～65 weight %, the disintegrating agent of 10～30 weight %, the odor mask of 1～20 weight %, the sweeting agent of 5～20 weight %, the edible essence of 0.5～3 weight % and the lubricant of 0.5～5 weight %.
2, Aminodyne Compound oral cavity disintegration tablet according to claim 1 is characterized in that: acetaminophen accounts for that 10～30 weight %, dextromethorphan hydrobromide account for 0.25～1 weight %, filler accounts for 10～60 weight % and disintegrating agent accounts for 10～20 weight %.
3, Aminodyne Compound oral cavity disintegration tablet according to claim 2 is characterized in that: acetaminophen accounts for 19.8 weight %, pseudoephedrine hydrochloride and accounts for 1.9 weight %, dextromethorphan hydrobromide and account for 0.6 weight %, chlorphenamine maleate and account for 0.2 weight %, filler and account for 39.6 weight %, disintegrating agent and account for 12.5 weight %, odor mask and account for that 14.8 weight %, sweeting agent account for 7.4 weight %, edible essence accounts for 2 weight % and lubricant accounts for 1.2 weight %.
4, according to each described Aminodyne Compound oral cavity disintegration tablet of claim 1～3, it is characterized in that this filler is water-soluble filler and/or water-insoluble filler, this water-soluble filler is mannitol, sorbitol and/or xylitol, and this water-insoluble filler is microcrystalline Cellulose, lactose, starch and/or pregelatinized Starch.
5,, it is characterized in that this disintegrating agent is cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose and/or crosslinked carboxymethyl fecula sodium according to each described Aminodyne Compound oral cavity disintegration tablet of claim 1～3.
6, according to each described Aminodyne Compound oral cavity disintegration tablet of claim 1～3, it is characterized in that this odor mask is trisodium citrate and/or fruity odor mask, this fruity odor mask is orange flavor, hami melon flavor, Fructus Fragariae Ananssae flavor, Fructus Musae flavor or Fructus Ananadis comosi flavor odor mask.
7,, it is characterized in that this sweeting agent is cyclamate, aspartame and/or stevioside according to each described Aminodyne Compound oral cavity disintegration tablet of claim 1～3.
8,, it is characterized in that this edible essence is Herba Menthae essence and/or fruit essence according to each described Aminodyne Compound oral cavity disintegration tablet of claim 1～3.
9,, it is characterized in that this lubricant is magnesium stearate and/or Pulvis Talci according to each described Aminodyne Compound oral cavity disintegration tablet of claim 1～3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510029230 CN1732938A (en) | 2005-08-31 | 2005-08-31 | Orally integrating tablet of compound paracetamol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510029230 CN1732938A (en) | 2005-08-31 | 2005-08-31 | Orally integrating tablet of compound paracetamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1732938A true CN1732938A (en) | 2006-02-15 |
Family
ID=36075694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510029230 Withdrawn CN1732938A (en) | 2005-08-31 | 2005-08-31 | Orally integrating tablet of compound paracetamol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1732938A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008089774A1 (en) * | 2007-01-22 | 2008-07-31 | Crd Saidal | Formulation of an orodispersible tablet based on coated paracetamol |
| CN101801349A (en) * | 2007-09-24 | 2010-08-11 | 宝洁公司 | Composition and method of stabilized sensitive ingredient |
| CN103169705A (en) * | 2011-12-23 | 2013-06-26 | 重庆医药工业研究院有限责任公司 | Compound orally disintegrating tablet containing chlorpheniramine and dextromethorphan |
-
2005
- 2005-08-31 CN CN 200510029230 patent/CN1732938A/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008089774A1 (en) * | 2007-01-22 | 2008-07-31 | Crd Saidal | Formulation of an orodispersible tablet based on coated paracetamol |
| CN101801349A (en) * | 2007-09-24 | 2010-08-11 | 宝洁公司 | Composition and method of stabilized sensitive ingredient |
| CN103169705A (en) * | 2011-12-23 | 2013-06-26 | 重庆医药工业研究院有限责任公司 | Compound orally disintegrating tablet containing chlorpheniramine and dextromethorphan |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1171586C (en) | Pharmaceutical compositions comprising monoamine oxidase B inhibitors | |
| CN100339127C (en) | Development of an anti-cough, anti-tussive and throat soothing herbal formulation | |
| CN100350908C (en) | Novel anti-allergic anti-inflammatory composite | |
| CN1682719A (en) | Enteric soluble coating slow releasing tablet containing huperzine A and preparing method | |
| CN1732938A (en) | Orally integrating tablet of compound paracetamol | |
| CN1723964A (en) | Medicine for treating cough and chronic bronchitis | |
| CN1628662A (en) | Medicine with abirritation | |
| CN1269480C (en) | Orally disintegrating tablet of loratadine and its preparation method | |
| CN1899523A (en) | Chinese medicine composition for treating acute and chronic largngopharyngitis and ts preparing method | |
| CN1872326A (en) | Composition of external remedy for treating hemorrhoids, and preparation method | |
| CN1211094C (en) | Medicine for treating pulmonary tuberculosis | |
| CN1478467A (en) | Rapid disintegrate tablet in oral and its preparation method | |
| CN1500487A (en) | Oral compound levocetirizine pseudoephedrine formulation and its preparation | |
| CN1931140A (en) | Orally disintegrated galantamine hydrobromide tablet and its prepn process | |
| CN1923182A (en) | Lacidipine tablets disintegrating in oral cavity and process for producing same | |
| CN1827134A (en) | Effervescence tablet for treating acute bronchitis, its preparation and quality control method | |
| CN1698618A (en) | Double layer tablet of artesunate and hydrochloric amodiaquine and preparation method thereof | |
| CN1293895C (en) | Oral disintegration tablet for laryngopathy and its preparing method | |
| CN1304021C (en) | Medicinal composition and its preparing method | |
| CN1679793A (en) | Xiaoaiping preparation against cancers and its making method | |
| CN1651030A (en) | Antivirus effervescent tablet and its preparation method | |
| CN1504215A (en) | Traditional Chinese medicine formulation for oral disease and its preparation method | |
| CN1429618A (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method | |
| CN1695617A (en) | Oral disintegration tablet of Amlodipine mesylate, and preparation method | |
| CN1528439A (en) | Medicinal drop pill for phlegm-reducing and cough relieving and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |